GALDERMA
28.9.2021 08:32:08 CEST | Business Wire | Press release
Galderma’s presence at the 2021 European Academy of Dermatology and Venereology (EADV) virtual congress on September 29 – October 2 will reveal new data and showcase the company’s sophisticated portfolio and services across the spectrum of dermatology. The company’s redesigned virtual booth will have dedicated areas presenting Galderma’s innovations in Consumer Care and Prescription Medicine.
Unveiling new data in Prescription Medicine
The congress will see the unveiling of exciting new data from Galderma relating to rosacea, acne, actinic keratosis, atopic dermatitis and prurigo nodularis. Attendees will have the opportunity to ask questions to the faculties during live Q&A sessions.
On Thursday, September 30, Professor Alison Layton^ will chair the symposium Personalizing Acne: Consensus of Experts to Optimize Acne Management . Together with her co-speakers, Professor Layton will provide practical solutions for longitudinal management of acne.
On the same day, Professor Gil Yosipovitch^ will present the symposium Prurigo Nodularis: From Patient to Pathway, which will discuss the multi-dimensional impact of the disease and reveal new clinical data for the investigational drug, nemolizumab*.
The symposium Moderate to Severe Atopic Dermatitis – A Disease in the Skin and Beyond will take place on Friday, October 1. Chaired by Professor Diamant Thaçi, the session will cover the role of neuro-immune cytokine IL-31 in atopic dermatitis and present emerging clinical data on the effect of nemolizumab* in blocking IL-31 signaling in the disease.
In the symposium New insights on Papulopustular Rosacea and Systemic Therapy on October 1, the speakers will discuss the importance of long-term management strategies in rosacea. Dr. James Q. Del Rosso^ will present original data on the impact of 52 weeks’ use of doxycycline 40mg MR on relapse rate in moderate to severe papulopustular rosacea patients.
On Saturday, October 2, Professor Rolf-Markus Szeimies^ and Professor Serge Mordon^ will host the industry hub Artificial Daylight Photodynamic Therapy: Advancing Actinic Keratosis Treatment . They will present the newly approved modality and main approved artificial daylight devices, as well as a demonstration video.
Galderma will also showcase its latest acne treatment, AKLIEF® (trifarotene) Cream, 0.005%, specifically designed for both facial and truncal acne.
Showcasing advanced solutions in Consumer Care
Visitors will be able to explore highlights from the CETAPHIL® portfolio of 61 products and the largest update in the brand’s 70-year history. As part of the update, CETAPHIL’s iconic, best-selling cleansers and moisturizers—Gentle Skin Cleanser, Daily Facial Cleanser, Moisturizing Cream, Moisturizing Lotion, and Advanced Relief Lotion—have been reformulated. With their dermatologist-backed blend of hydrating and skin-nourishing ingredients, including niacinamide, panthenol and hydrating glycerin, the range of products helps improve the overall resilience of sensitive skin.
CETAPHIL’s latest research will be unveiled through two dedicated symposia. On Thursday, September 30, Dr. Krzysztof Piotrowski^ will chair the symposium Pediatric Atopic Dermatitis: Current Developments . Professor Adelaide Hebert^ will focus on the latest updates in the field of pediatric atopic dermatitis while Dr. Mark Koh^ will then present his findings and answer the question, “Is it possible to prevent atopic dermatitis from birth?”.
On Friday, October 1, Professor Giovanni Pellacani^ will chair the symposium Advancing Sensitive Skin: Diagnosis, Morphological Traits and Epidemiology . Key speakers Professor Laurent Misery^ and Dr. Emilie Brenaut^ will present their latest research findings and focus on what sensitive skin is, how it can be distinguished from non-sensitive skin and methods for profiling.
Experts from BENZAC® and LOCERYL® will present new findings relating to maskne and onychomycosis through two industry hubs: on Thursday, September 30, Dr. Markus Reinholz^ will chair The Many Faces of Maskne – a New Skin Burden / an Upcoming Disease , featuring speaker Dr. Anne-Charlotte Kuna^. On Friday, October 1, Dr. Dieter Reinel^ will host Onychomycosis Update – Novel Findings: Prevalence, Epidemiology and Topical Therapy .
* Nemolizumab is an investigational drug not approved for any indication in any jurisdiction.
^All speakers are paid consultants of Galderma.
“Galderma is a proud partner of the EADV Congress and we are thrilled to be showcasing our latest innovations and data across our dermatology portfolio. As a company, we are fully committed to advancing dermatology for every skin story.”
BALDO SFORZOLINI, Ph.D. GLOBAL HEAD OF R&D, GALDERMA
|
About Galderma
Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story. For more information:
About prurigo nodularis
Prurigo nodularis (PN) is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated intense unrelenting itch.10
While PN can occur at any age, it is most likely to affect people between the ages of 40 and 69, frequently leading to severe impairment in quality of life.11
The global prevalence of PN is unknown as there are no studies describing the epidemiology of the condition. In the U.S., the latest estimate is that PN affects 52.9 people in every 100,000. In the European context, rates of between 0.65 and 11.1 per 10,000 population have been reported. In addition to natural variation, this relatively wide range of estimates is partly due to differences in case definition and the representativeness of the study populations.12
About nemolizumab
Nemolizumab is a first-in-class humanized monoclonal antibody directed against the IL-31 receptor alpha that blocks signaling from IL-31.6
IL-31 plays a key role in multiple disease mechanisms in both atopic dermatitis and prurigo nodularis, a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated severe pruritus (itching). With its unique role in directly stimulating sensory neurons related to itch and contributing to inflammation and barrier dysfunction, IL-31 is the bridge between the immune and nervous systems while directly acting on structural cells in the skin. Nemolizumab, initially developed by Chugai Pharmaceutical Co., Ltd., was subsequently licensed to Galderma in 2016 – worldwide except Japan and Taiwan. Nemolizumab is an investigational agent under clinical development for the treatment of atopic dermatitis and prurigo nodularis and its safety and efficacy have not been fully evaluated by any regulatory authority. Nemolizumab was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) in December 2019 for the treatment of pruritus associated with prurigo nodularis.
About AKLIEF
In the European Union, AKLIEF®
(trifarotene 50 mcg/g cream) is indicated for the cutaneous treatment of acne vulgaris of the face and/or the trunk in patients from 12 years of age and older, when many comedones, papules and pustules are present. It is the only topical retinoid that specifically targets retinoic acid receptor gamma (RAR-γ), the most common RAR in the skin.13, 14
National marketing authorizations across concerned European member states will follow in 2020.
About CETAPHIL
CETAPHIL was developed by a leading pharmacist more than 70 years ago as a gentle, yet powerful formula to clean without stripping and moisturize without clogging. CETAPHIL is the #1 dermatologist-recommended brand in Germany and the #1 doctor-recommended sensitive skincare brand in the U.S. and is now available in Switzerland. New additions to the brand are regularly developed with the help of leading global skincare experts, providing innovative skincare technologies for sensitive skin that help restore, protect, and maintain skin health every day. For more information, visit www.cetaphil.com
.
About BENZAC
BENZAC is an acne brand proposing treatments based on Benzoyl Peroxide active ingredient, as well as acne specific regimen companion products (including cleansers and moisturizers).
About LOCERYL
LOCERYL is the number one nail antifungal brand globally.16
Its treatment is based on amorolfine active ingredient.
-----------------
1. Tan J, et al. Prevalence and severity of facial and truncal acne in a referral cohort. J Drugs Dermatol. 2008;7(6):551–6.
2. Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol 2013;168:474–85.
3. Hay RJ, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol 2014;134:1527–34.
4. Del Rosso JQ, et al. A closer look at truncal acne vulgaris: prevalence, severity, and clinical significance. J Drugs Dermatol 2007;6:597–600.
5. Layton AM, et al. Reviewing the global burden of acne: how could we improve care to reduce the burden? Br J Dermatol 2021;184:219–225.
6. Saleem M. et al. Interleukin-31 pathway and its role in atopic dermatitis: a systematic review. J Dermatolog Treat. 2017;28(7):591-599. DOI: 10.1080/09546634.2017.1290205
7. Langan S. et al. Atopic dermatitis. The Lancet. 2020;396(10247):345-360. DOI: https://doi.org/10.1016/S0140-6736(20)31286-1
8. Nutten S. Atopic Dermatitis: Global Epidemiology and Risk Factors. Ann Nutr Metab 2015;66(suppl1):8-16. DOI: https://doi.org/10.1159/000370220
9. Atopic Eczema – Symptoms. NHS. Available from: https://www.nhs.uk/conditions/atopic-eczema/symptoms/ Accessed: March 2021.
10. Galderma. Data on File.
11. Atopic Eczema – Symptoms. NHS. Available from: https://www.nhs.uk/conditions/atopic-eczema/symptoms/ Accessed: March 2021
12. Morgan LI. Christopher. Epidemiology of prurigo nodularis in England. 2021.
13. Aubert J, et al. Br J Dermatol 2018;179:442–56.
14. Fisher GJ, et al. J Biol Chem 1994;269(32):20629–35.
15. Health Canada. Approval of Aklief. Available at: Register of Innovative Drugs - Canada.ca (last access December 2019)
16. Nicholas Hall’s global CHC database, DB6
View source version on businesswire.com: https://www.businesswire.com/news/home/20210927005918/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kao’s Laurier Launches New Brand Communication Initiative across Asia: Strengthening Global Integration as a Core Brand in Kao’s Asian Business4.3.2026 03:10:00 CET | Press release
Starting on International Women’s Day, March 8, Kao Corporation (TOKYO:4452) will launch new brand communication campaign in nine Asian countries and regions for its feminine sanitary product brand, Laurier, which is the core of its Asian business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303996141/en/ Laurier Campaign Key Visual Laurier aims to help create more supportive and understanding environments around menstruation, so that women can feel more at ease, both physically and emotionally, under the key message “Comfort, Made Together,” which will be implemented simultaneously across Asia. Kao aims to further develop Laurier as a global brand. Laurier, one of the core brands supporting Kao’s consumer care business in Asia, has been promoting globally integrated operations since 2023. Across all nine Asian countries and regions including Japan, Laurier has been working to unify product specifications and consolida
FIFA World Cup 2026™ Mascots and Representatives from the New York New Jersey Host Committee, U.S. Soccer Federation, Mexico Football Federation and Canada Soccer Light the Empire State Building to Celebrate 100 Days to Go Until the FIFA World ...3.3.2026 23:06:00 CET | Press release
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303105064/en/ FIFA World Cup 2026™ Mascots and Representatives from the New York New Jersey Host Committee, U.S. Soccer Federation, Mexico Football Federation and Canada Soccer Light the Empire State Building to Celebrate 100 Days to Go Until the FIFA World Cup 2026™ FIFA World Cup 2026™ Mascots and Representatives from the New York New Jersey Host Committee, U.S. Soccer Federation, Mexico Football Federation and Canada Soccer Light the Empire State Building to Celebrate 100 Days to Go Until the FIFA World Cup 2026™ On Tuesday, March 3, the Empire State Building will rotate in the colors of the flags of the three host countries – the United States, Canada, and Mexico – to mark 100 days to go until the FIFA World Cup 2026™. Earlier today, the Empire State Building hosted a special tower lighting ceremony with Alex Lasry, CEO of the FIFA World Cup 26™ New York New Jersey Host C
SES Publishes 2025 Annual Report3.3.2026 21:41:00 CET | Press release
SES S.A. has today published its 2025 Annual Report, following the announcement of the company’s full year financial results for the 12 months ended 31 December 2025. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry leadership—backed by a track record of bringing innovation “firsts” to market. As a trusted partner to customers and the global space ecosystem, SES is driving impact that goes far beyond coverage. The company is headquartered
Xsolla Expands Global Payment Coverage Across 18 Markets With 6 Trusted Local Payment Methods to Help Developers Reach New Players Worldwide3.3.2026 18:00:00 CET | Press release
Amazon Pay Japan, Zain Cash, Tamara, M-Pesa, Zamtel, and the Aircash app and vouchers are now available through Xsolla Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced a major expansion of its global payments portfolio across 18 markets in Europe, the Middle East, Africa, and Asia. As developers continue to expand into high-growth and emerging markets, this expansion enables developers to reach new paying users, improve conversion rates, and deliver payment experiences tailored to local player preferences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303816373/en/ Graphic: Xsolla The newly supported payment methods include:Local Amazon Pay in Japan, with over 100 million registered Amazon Japan accounts, provides fully localized checkout experiences in Japanese Yen Zain Cash in Iraq is expanding access to mobile-first payment options in a rapidly
SES Announces Annual General Meeting of Shareholders3.3.2026 17:42:00 CET | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Annual General Meeting of SES, Société Anonyme, to be held at the Company’s registered office at Château de Betzdorf, L-6815 Betzdorf (the “Company”), Luxembourg, on Thursday 2 April 2026 at 10:30 a.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Presentation by the Chairman of the Board of Directors of the 2025 activities report of the Board of Directors Presentation of the main developments during 2025 and of the outlook Presentation of the audit report Approval of annual financial statements, balance sheet and profit and loss account as of 31 December 2025 Approval of consolidated financial statements as of 31 December 2025 Allocation of 2025 profits and transfers between reserve accounts Discharge of the members of the Board of Directors Determination of the number of Directors Confirmation of the co-optation of Joseph Cohen and determination o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom